Krystal Biotech to Present at 2018 Cell & Gene Meeting on the Mesa
PITTSBURGH, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Suma Krishnan, founder and chief operating officer, will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa to be held October 3-5 in La Jolla, California.
This conference is the largest partnering meeting organized specifically for the cell and gene therapy sector, providing the opportunity for participants to establish key relationships and accelerate business development.
Organized by ARM and the Sanford Stem Cell Clinical Center at UC San Diego, the Cell & Gene Meeting on the Mesa is a three-day conference featuring three distinct parts, the program’s two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium. The event’s Partnering Forum on October 3-4 features more than 70 dedicated company presentations in addition to over 90 panelists and featured speakers.
The following are specific details regarding Krystal’s presentation at the conference:
Event: 2018 Cell & Gene Meeting on the Mesa – Partnering Forum Date: Wednesday, October 3 Time: 2:45 p.m. PT Location: Estancia La Jolla Hotel & Spa, La Jolla Ballroom 2
A live video webcast of all company presentations will be available at: http://www.meetingonthemesa.com/webcast and will also be published on the conference website shortly after the event.
Please visit www.meetingonthemesa.com for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Parsons at firstname.lastname@example.org and interested media should contact Lyndsey Scull at email@example.com.
About Krystal BiotechKrystal Biotech, Inc. (NASDAQ:KRYS) is a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases. For more information, please visit http://www.krystalbio.com.
Forward-Looking Statements This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding the potential of KB103 to treat the underlying causes of DEB, the timetable for bringing GMP manufacturing in-house and the potential for rapid development of the company’s clinical programs. You can identify forward-looking statements because they contain words such as “believes” and “expects.” Forward-looking statements are based on Krystal’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Krystal’s filings with the Securities and Exchange Commission, including its registration statement on Form S-1 and Form 10-K, as amended from time to time, under the caption “Risk Factors.”
Investors: Ashley R. Robinson LifeSci Advisors firstname.lastname@example.org
Media:Darren Opland, PhD LifeSci Public Relations email@example.com
Source: Krystal Biotech, Inc.